This subset, herein called CK2, was associated with a higher incidence of TP53 aberrations, chemo-refractoriness and a shorter OS at multivariate analysis.12 Furthermore, CK2 CLL cases have a distinct mRNA expression profile with a deregulation of genes involved in cell-cycle control and DNA damage response.12 In the present study we included 522 patients and we combined data derived from stimulated chromosome banding analysis with the IGHV mutational status in order to improve the prognostic and predictive power of these markers. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.